1. Marx N, Husain M, Lehrke M, et al. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 2022; 146: 1882-94.
2.
Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol 2021; 18: 58-68.
3.
Chinese Elderly Type 2 Diabetes P, G Treatment of Clinical Guidelines Writing, E Geriatric, et al. [Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)]. Zhonghua Nei Ke Za Zhi 2022; 61: 12-50.
4.
Cheng J, Huang H, Chen Y, et al. Nanomedicine for diagnosis and treatment of atherosclerosis. Adv Sci (Weinh) 2023; 10: e2304294.
5.
Lucchi T Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly. Minerva Med 2021; 112: 804-16.
6.
Chait A, Eckel RH, Vrablik M, et al. Lipid-lowering in diabetes: an update. Atherosclerosis 2024; 394: 117313.
7.
Rostoff P, Drwila-Stec D, Majda A, et al. Lipophilic index of serum phospholipids in patients with type 2 diabetes and atherosclerotic cardiovascular disease: links with metabolic control, vascular inflammation and platelet activation. Cardiovasc Diabetol 2024; 23: 409.
8.
Chen Y, Ye X, Escames G, et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell Mol Biol Lett 2023; 28: 51.
9.
Corcoran SE, Halai R, Cooper MA. Pharmacological inhibition of the nod-like receptor family pyrin domain containing 3 inflammasome with MCC950. Pharmacol Rev 2021; 73: 968-1000.
10.
Toldo S, Mezzaroma E, Buckley LF, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther 2022; 236: 108053.
11.
Ye J, Li L, Wang M, et al. Diabetes mellitus promotes the development of atherosclerosis: the role of NLRP3. Front Immunol 2022; 13: 900254.
12.
Tan Y, Chen S, Gao T, et al. Exploring the role of NLRP3 infalmmasome in diabetes: a literature review and bibliometric analysis. Front Endocrinol (Lausanne) 2024; 15: 1443798.
13.
Wen RM, Lyu HY, Chang B, et al. [Role of NLRP3 inflammasome in diabetes mellitus and exercise intervention]. Sheng Li Xue Bao 2023; 75: 788-98.
14.
Liu M, Xia P, Tan Z, et al. Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: a systematic review and dose-response meta-analysis. Front Cardiovasc Med 2022; 9: 989574.
15.
Liu YC, Tsai JP, Wang LH, et al. Positive correlation of serum fibroblast growth factor 23 with peripheral arterial stiffness in kidney transplantation patients. Clin Chim Acta 2020; 505: 9-14.
16.
Grund A, Sinha MD, Haffner D, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease-a pediatric perspective. Front Pediatr 2021; 9: 702719.
17.
Kurpas A, Supel K, Wieczorkiewicz P, et al. Fibroblast growth factor 23 and cardiovascular risk in diabetes patients-cardiologists be aware. Metabolites 2022; 12: 498.
18.
Bi J, Zheng M, Li K, et al. Relationships of serum FGF23 and alpha-klotho with atherosclerosis in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2024; 23: 128.
19.
Kong P, Cui ZY, Huang XF, et al. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention. Signal Transduct Target Ther 2022; 7: 131.
20.
Honda Y, Ishigami J, Karger AB, et al. The association of fibroblast growth factor 23 at mid-life and late-life with subsequent risk of cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J Plus 2022; 13: 100124.
21.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889-934.
22.
Zhang X, McDonald JG, Aryal B, et al. Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis. Proc Natl Acad Sci USA 2021; 118: e2107682118.
23.
Jin Y, Liu Y, Xu L, et al. Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis. Cell Death Dis 2022; 13: 512.
24.
Hsu CC, Fidler TP, Kanter JE, et al. Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis. Diabetes 2023; 72: 999-1011.
25.
Pasterkamp G, van der Laan SW, Hoefer IE. Hunt for the (Multi)-Marker Grail in the Diverse Landscape of Atherosclerosis. Arterioscler Thromb Vasc Biol 2021; 41: 1789-91.
26.
Chen S, Shen Y, Liu YH, et al. Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2021; 20: 64.
27.
Maida CD, Daidone M, Pacinella G, et al. Diabetes and ischemic stroke: an old and new relationship an overview of the close interaction between these diseases. Int J Mol Sci 2022; 23: 2397.
28.
Figurek A, Rroji M, Spasovski G. FGF23 in chronic kidney disease: bridging the heart and anemia. Cells 2023; 12: 609.
